Circulating microRNA as a marker for predicting liver disease progression in patients with chronic hepatitis B

Abstract

Introduction: Hepatitis B virus (HBV) constitutes an important risk factor for cirrhosis and hepatocellular carcinoma (HCC). The link between circulating microRNAs and HBV has been previously reported, although not as a marker of liver disease progression in chronic hepatitis B (CHB). The aim of this study was to characterize miRNA expression profiles between CHB with and without cirrhosis or HCC. Methods: A total of 12 subjects were recruited in this study. We employed an Affymetrix Gene Chip miRNA 3.0 Array to provide universal miRNA coverage. We compared microRNA expression profiles between CHB with and without cirrhosis/HCC to discover possible prognostic markers associated with the progression of CHB. Results: Our results indicated 8 differently expressed microRNAs, of which miRNA-935, miRNA-342, miRNA-339, miRNA-4508, miRNA-3615, and miRNA-3200 were up-regulated, whereas miRNA-182 and miRNA-4485 were down-regulated in patients with CHB who progressed to cirrhosis/HCC as compared to those without progression. Conclusions: We demonstrated the differential expression of between patients with HBV without cirrhosis/HCC and those who had progressed to these more severe conditions. These miRNAs may serve as novel and non-invasive prognostic markers for early detection of CHB-infected patients who are at risk of progression to cirrhosis and/or HCC.

The diagnostic and prognostic value of plasma microRNA‑125b‑5p in patients with multiple myeloma

“…Plasma miRNAs have been previously reported in the context of some cancers (4,13,14). In the present study, we performed an miRNA microarray analysis to elucidate the expression profiles of plasma miRNA in six MM patients and six healthy individuals.…”

miR-935 Inhibits Oral Squamous Cell Carcinoma and Targets Inositol Polyphosphate-4-phosphatase Type IA (INPP4A)

“…Conversely, miR-935 is reported as an onco-miR in gastric cancer that inhibits SOX7 (55), in non-small cell lung cancer that inhibits IL-27 (41), in non-small-cell lung cancer that inhibits SOX7 (56), in hepatocellular carcinoma that inhibits SOX7 and activates c-Myc and cyclin D1 (57), in pancreatic carcinoma that inhibits INPP4A and possibly p27 (58), and in colorectal cancer that targets INPP4A (59). In addition, overexpression of miR-935 has been reported in stathmindepleted neuroblastoma (60), Helicobacter pylori-positive gastric cancer (using Gene Expression Omnibus database) (61), stage-I endometrioid endometrial cancer (62), bladder cancer (63), and chronic hepatitis B that progressed to cirrhosis/hepatocellular carcinoma (64). In high-grade precancerous cervical lesions, methylation levels of miR-935 were remarkably high (65).…”

Diagnostic value of circulating microRNAs for liver cirrhosis: a meta-analysis

“…However, the diagnostic accuracies are inconsistent [ 43 – 45 ]. Previous studies have reported miRNAs as biomarkers of liver cirrhosis [ 46 , 47 ]. This study is the first meta-analysis to assess the diagnostic value of circulating miRNAs in identifying liver cirrhosis.…”